Home・Listă Acțiuni・MannKind Corp

MannKind Corp

Deschisă

SectorSănătate

3.96 4.21

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.7800000000000002

Maxim

3.88

Indicatori cheie
By Trading Economics
Venit	-671K -17M
Vânzări	-22M 90M
P/E Medie Sector	140.5 64.641
EPS	-0.02
Marjă de profit	-18.431
Angajați	591
EBITDA	5M 2.5M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+130.26% upside

Dividende
By Acuity
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	353M 1.2B
Deschiderea anterioară	-0.25
Închiderea anterioară	3.96

Sentimentul știrilor

By Acuity

50%

151 / 340 Clasament în Healthcare

MannKind Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 22:51 UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

31 iul. 2026, 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

30 iul. 2026, 18:41 UTC

Event

News

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

29 iul. 2026, 19:47 UTC

News

Event

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

28 iul. 2026, 21:01 UTC

News

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

27 iul. 2026, 22:06 UTC

MannKind Corp shares are higher in after-market trading, despite earlier declines. No specific news was identified to explain the price movement.

24 iul. 2026, 21:01 UTC

Event

MannKind Corp shares are rising in after-market trading following FDA approval of Furoscix ReadyFlow™ for treating edema in heart failure and chronic kidney disease.

23 iul. 2026, 10:36 UTC

MannKind Corp shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite declines in the broader tech sector.

22 iul. 2026, 21:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting a gain since Wednesday's close, despite remaining below the 20-day moving average.

21 iul. 2026, 22:11 UTC

MannKind Corp shares rose in after-market trading, reflecting a broader rebound in technology stocks and strong interest in semiconductor and AI investments.

Comparație

Modificare preț

MannKind Corp Așteptări

Obiectiv de preț

By TipRanks

130.26% sus

Prognoză pe 12 luni

Medie 8.75 USD 130.26%

Maxim 14 USD

Minim 4.75 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMannKind Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor MannKind Corp - Dist în ultimele 3 luni.

Sentiment

By Acuity

151 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.